Fairfield Financial Advisors, LTD Neurocrine Biosciences Inc Transaction History
Fairfield Financial Advisors, LTD
- $284 Billion
- Q4 2024
A detailed history of Fairfield Financial Advisors, LTD transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Fairfield Financial Advisors, LTD holds 100 shares of NBIX stock, worth $11,759. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100
Previous 100
-0.0%
Holding current value
$11,759
Previous $11.5 Million
18.47%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding NBIX
# of Institutions
655Shares Held
96.5MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.67 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.19 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$575 Million0.03% of portfolio
-
Dodge & Cox San Francisco, CA3.02MShares$355 Million0.26% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$298 Million0.06% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.2B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...